ForSight VISION5 is a Menlo Park, CA–based developer of non-invasive products intended to replace eye drops and deliver sustained therapy for anterior segment diseases including glaucoma, dry eye, and allergy. The company, founded in January 2011 as the fifth company to emerge from the ophthalmic incubator ForSight Labs, is led by CEO John Maroney. Its core product is the Helios insert, a novel, non-invasive delivery system designed to allow glaucoma and ocular hypertensive patients to continually receive medication. ForSight VISION5 has completed enrollment of over 160 subjects in a randomized, active-controlled Phase 2 study for the Helios insert. It completed a $15M Series C financing led by H.I.G. BioVentures, with participation from existing investors Morgenthaler Ventures, Versant Ventures, Technology Partners and Delphi Ventures. As part of the financing, Aaron Davidson of H.I.G. BioVentures joined the company's Board of Directors.

Total raised

$15M

Funding rounds

1

Latest round

Series C

Latest activity

Apr 2014